Aviva’s Omnicell OMCL Stock Holding History

Aviva’s Portfolio OMCL Stock Details OMCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,686	Closed	-$1.13M	–	949
2021 Q1	$1.13M	Buy	+8,686	New	+$1.11M	0.01%	893

Other funds holding OMCL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aviva's OMCL Position: Q2 2021 in Review

Aviva sold out of Omnicell (OMCL) in Q2 2021, closing a stake of 8,686 shares — an estimated $1.13M sold.

Aviva first reported a position in OMCL in Q1 2021 and held it in 1 quarter. The position peaked at $1.13M in Q1 2021. 377 funds tracked by Wall St. Rank hold OMCL as of Q2 2021.

Aviva reported no remaining Omnicell position as of Q2 2021 after selling out during the quarter.
Aviva sold 8,686 Omnicell shares in Q2 2021, an estimated $1.13M.
Aviva first reported a position in Omnicell in Q1 2021 and held it in 1 quarter.
Aviva's Omnicell position peaked at $1.13M in Q1 2021.
377 funds tracked by Wall St. Rank held Omnicell as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.